


COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



Immuno-Oncology Diagnostics

Market Forecasts for Immuno-Oncology Diagnostics
with COVID-19 Impact and Updates.

Including Executive/Consultant Guides and Customized Forecasting/Analysis.
2021 to 2025





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

i. Market Guides.....	17
i. Situation Analysis & Impact of COVID-19 Pandemic	18
ii. Guide for Executives and Marketing Staff	21
iii. Guide for Investment Analysts and Management Consultants	22
1. Introduction and Market Definition	23
1.1 What are Immuno-Oncology Diagnostics?	24
1.2 Immuno-oncology – the looming cure	26
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role.....	28
1.3 Market Definition	29
1.3.1 Market Size	29
1.3.2 Currency	29
1.3.3 Years	29
1.4 Methodology	30
1.4.1 Authors.....	30
1.4.2 Sources	30
1.5 U.S. Medical Market and laboratory Testing - Perspective	31
1.5.1 U.S. Medicare Expenditures for Laboratory Testing	32
2. Immunotherapy – Guide to Immune Technologies	34
2.0 The Immune System.....	35
2.0.1 Innate immune system	36
2.0.1.1 Surface barriers	37
2.0.1.2 Inflammation	38

2.0.1.3 Complement system	38
2.0.1.4 Cellular barriers.....	39
2.0.1.5 Natural killer cells.....	40
2.0.2 Adaptive immune system	41
2.0.2.1 Lymphocytes	41
2.0.2.2 Killer T cells	42
2.0.2.3 Helper T cells	44
2.0.2.4 Gamma delta T cells	45
2.0.2.5 B lymphocytes and antibodies.....	45
2.0.3 Tumor immunology – the immune surveillance system	47
2.1 Immuno Oncology Diagnostics.....	49
2.1.1 Checkpoint Assays	49
2.1.1.1 Outlook for Checkpoint Assays	54
2.1.2 Cytokine Assays	55
2.1.2.1 Outlook for Cytokine Assays	55
2.1.3 Genomic Germline	56
2.1.3.1 Outlook for Genomic Germline.....	57
2.1.4 Genomic Tumour	57
2.1.4.1 Outlook for Genomic Tumour	60
2.1.5 Tumor Microenvironment	61
2.1.5.1 Outlook for Tumor Micro Environment	62
2.1.6 Others.....	62
2.1.6.1 Outlook for Other Diagnostics	62
3. Industry Overview	63
3.1 Players in a Dynamic Market	64

3.1.1 Academic Research Lab.....	64
3.1.2 Diagnostic Test Developer.....	65
3.1.3 Genomic Instrumentation Supplier	65
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier	66
3.1.4 Pharmaceutical/Reagent Supplier.....	66
3.1.5 Independent Testing Lab.....	66
3.1.6 Public National/regional lab	67
3.1.7 Hospital lab.....	67
3.1.8 Physician Lab	67
3.1.9 Audit Body	68
3.1.10 Certification Body.....	68
4. Market Trends.....	70
4.1 Factors Driving Growth.....	71
4.1.1 Outcome potential	71
4.1.2 Companion Diagnostics	72
4.1.3 Funding	72
4.1.4 Technology Environment	72
4.1.5 Target Solutions	73
4.2 Factors Limiting Growth	74
4.2.1 Complex Role of Diagnostics	74
4.2.2 Clinical Trials Role.....	75
4.2.3 Protocols	75
4.3 Diagnostic Technology Development	77
4.3.1 Combinations - Issues and Complexity	77
4.3.2 Shifting Role of Diagnostics.....	79

- 4.3.3 Multiplexing and Foundation One80
- 4.3.4 The Disruption Dynamic81
- 4.3.5 The Race for Biomarkers81
- 4.3.6 The Next Five Years82
- 5. Cancer Immuno-Oncology Diagnostics Recent Developments83
 - 5.1 Recent Developments – Importance and How to Use This Section84
 - 5.1.1 Importance of These Developments84
 - 5.1.2 How to Use This Section84
 - OncoDNA use HalioDx to Expand into North America.....84
 - Adaptive Biotechnologies, Q2 Solutions Sign Agreement for ImmunoSeq Assay85
 - Qiagen Expands Immuno-Oncology Portfolio86
 - Immune Profiling System Redirected to Fight COVID-1987
 - IncellDx Awarded PD-L1 Detection Patent.....89
 - FDA Approves CDx for Trastuzumab.....90
 - Promega Nabs CE Mark for Microsatellite Instability IVD91
 - ArcherDx partners with AstraZeneca for Immuno-Oncology92
 - Germline Results Guides Precision Therapy93
 - Agilent PD-L1 Assay Gets FDA Approval97
 - Bayer, OrigiMed Form Companion Diagnostic Development Alliance98
 - Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy98
 - SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures99
 - Biocare Medical Launches 7 Novel IVD Antibodies 100
 - Oncocyte to Acquire Insight Genetics for \$12M..... 102
 - Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm 103

Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment	104
Generex to Merge with NuGenerex Immuno-Oncology	105
Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies	107
Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative Breast Cancer	108
Icon Acquires MolecularMD.....	109
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca	110
Tumor Mutational Burden as Predictor of Immunotherapy Success	112
6. Profiles of Key Immunotherapy Companies	116
10X Genomics.....	117
Abbott Laboratories	118
Abcam.....	120
Adaptive Biotechnologies	122
Aethlon Medical	123
Agena Bioscience	124
Angle plc	126
Apocell	127
ARUP Laboratories	128
Beckman Coulter.....	130
Becton Dickinson	131
Bioarray Genetics	133
BioCartis.....	134
Biocept	135
Biodesix Inc.....	137
BioFluidica	138

BioGenex	140
bioMérieux.....	142
Bio-Rad	143
Bio-Techne.....	144
Bristol-Myers Squibb	146
Cancer Genetics	148
Caris Molecular Diagnostics	150
CellMax Life	152
Charles River Laboratories	153
Chronix Biomedical	155
Circulogene	156
Clearbridge BioMedics	157
Clinical Genomics	159
Cynvenio	160
Cytolumina Technologies Corp.	161
CytoTrack	162
Dako (Agilent).....	163
Diagnologix LLC	165
Epic Sciences	166
Exosome Diagnostics.....	167
Fluidigm Corp.....	169
Fluxion Biosciences	171
Foundation Medicine.....	172
Freenome	173
Genomic Health	174

GenomOncology	176
GRAIL	177
Guardant Health	179
HaliuDx.....	180
Horizon Discovery	181
HTG Molecular Diagnostics.....	183
iCellate	185
Illumina.....	186
Incell Dx	188
Inivata.....	189
Integrated Diagnostics.....	190
Invivoscribe	191
Leica Biosystems	193
Luminex.....	194
MDx Health.....	196
Merck & Co., Inc.....	198
MIODx	199
Molecular MD	200
MRM Proteomics Inc.....	201
Myriad Genetics/Myriad RBM	202
Nanostring	204
Natera.....	206
Neogenomics	208
New Oncology	210
Oncocyte	211

Ortho Clinical Diagnostics	212
Perkin Elmer	213
Personal Genome Diagnostics.....	215
Pfizer.....	216
Promega.....	217
Protagen Diagnostics.....	219
Qiagen.....	220
Quanterix.....	222
Rarecells SAS.....	223
Roche Diagnostics.....	225
Siemens.....	227
Silicon Biosystems.....	228
SkylineDx.....	229
SRI International	230
Sysmex	232
Thermo Fisher.....	233
Trovagene	235
Vortex Biosciences.....	236
7. The Global Market for Immuno-Oncology Diagnostics.....	237
7.1 Global Market Overview by Country	238
7.1.1 Table – Global Market by Country.....	238
7.1.2 Chart - Global Market by Country.....	239
7.2 Global Market by Assay Type - Overview	240
7.2.1 Table – Global Market by Assay Type	240
7.2.2 Chart – Global Market by Assay Type – Base/Final Year Comparison.....	241

7.2.3 Chart – Global Market by Assay Type – Base Year	242
7.2.4 Chart – Global Market by Assay Type – End Year	243
7.2.5 Chart – Global Market by Assay Type – Share by Year	244
7.2.6 Chart – Global Market by Assay Type – Segments Growth.....	245
8. Global Immuno-Oncology Diagnostic Markets – By Assay Type	246
8.1 Checkpoint	247
8.1.1 Table Checkpoint – by Country	247
8.1.2 Chart - Checkpoint Growth.....	248
8.2 Cytokine	249
8.2.1 Table Cytokine – by Country	249
8.2.2 Chart - Cytokine Growth.....	250
8.3 Germline Genetic	251
8.3.1 Table Germline Genetic – by Country.....	251
8.3.2 Chart - Germline Genetic Growth	252
8.4 Genetic Tumor	253
8.4.1 Table Genetic Tumor – by Country	253
8.4.2 Chart - Genetic Tumor Growth	254
8.5 Tumor Microenvironment.....	255
8.5.1 Table Tumor Microenvironment – by Country	255
8.5.2 Chart – Tumor Microenvironment Growth	256
8.6 Other.....	257
8.6.1 Table Other – by Country.....	257
8.6.2 Chart - Other Growth	258
9. Appendices.....	259
9.1 FDA Cancer Drug Approvals by Year.....	260

9.2 Clinical Trials Started 2010 to 2016261

9.3 Prevalence of Cancer Treatments262

Table of Tables

Table 1 List of Cancers by Mortality	27
Table 2 Lab Spending 2014 to 2024	33
Table 3 Overview of Innate and Adaptive Immunity	36
Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment	51
Table 5 FDA Approved Companion diagnostics in Cancer treatment.....	58
Table 6 Market Players by Type.....	64
Table 7 Five Factors Driving Growth	71
Table 8 Three Factors Limiting Growth.....	74
Table 9 - Global Market by Region.....	238
Table 10 Global Market by Assay Type	240
Table 11 Checkpoint by Country	247
Table 12 Cytokine by Country	249
Table 13 Germline Genetic by Country	251
Table 14 Genetic Tumor by Country.....	253
Table 15 Tumor Microenvironment by Country	255
Table 16 Other by Country	257

Table of Figures

Figure 1 Cancer Death Rates – USA, CDC26

Figure 2 Clinical Lab Spending 2014 to 202432

Figure 3 Helper T Cell Roles44

Figure 4 Antibody Diagram46

Figure 5 Macrophages attack a Cancer Cell47

Figure 6 The Tumour Micro Environment.....61

Figure 7 Comparing IO Diagnostic and Traditional Testing.....79

Figure 8 Growth rates of IO Diagnostic Technologies.....82

Figure 9 Global Market Density Chart239

Figure 10 Global Market by Assay Type - Base vs. Final.....241

Figure 11 Global Market by Assay Type Base Year242

Figure 12 Global Market by Assay Type End Year.....243

Figure 13 Assay Type Share by Year244

Figure 14 Assay Type Segments Growth.....245

Figure 15 Checkpoint Growth248

Figure 16 Cytokine Growth250

Figure 17 Germline Genetic Growth252

Figure 18 Genetic Tumor Growth254

Figure 19 Tumor Microenvironment Growth256

Figure 20 Other Growth.....258

Figure 21 FDA Cancer Drug Approvals by Year260

Figure 22 Clinical Trials for Immunotherapy by Year261

Figure 23 Pie Chart of Prevalence of Cancer Treatments262